Clinical trial
Amifostine With or Without Epoetin Alfa in Treating Patients With…
NCT00003681 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Unknown status
Key facts
| NCT number | NCT00003681 |
|---|---|
| Title | Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome |
| Official title | Phase II Multicenter Study of Amifostine in Patients With Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Myelodysplastic Syndromes |
| Intervention type | Biological, Drug |
| Interventions | epoetin alfa, amifostine trihydrate |
| Enrollment | 50 |
| Start date | Aug 1, 1998 |
| First posted | Aug 4, 2004 |
| Last update posted | May 12, 2009 |
| Countries | Austria, Belgium, Czechia, Netherlands, Portugal, Slovakia, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: